Peer Review

Rustum Roy in his Commentary (“ ‘Soft Cheating’ Is More Harmful To Science Than Cases Of Outright Fraud,” The Scientist, Sept. 18, 1989, page 14) is confused in his allegation that the “funding process [of peer review] Is... tainted by a built-in conflict of interest.” Though it is true that the scientists most likely to review a proposal are the very ones whose pool of available money will be depleted if they give a proposal a top grade, this fact nearly en

Written byMichael Stuart Loop
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Rustum Roy in his Commentary (“ ‘Soft Cheating’ Is More Harmful To Science Than Cases Of Outright Fraud,” The Scientist, Sept. 18, 1989, page 14) is confused in his allegation that the “funding process [of peer review] Is... tainted by a built-in conflict of interest.” Though it is true that the scientists most likely to review a proposal are the very ones whose pool of available money will be depleted if they give a proposal a top grade, this fact nearly ensures that only the consensus best will be funded..

Every review group knows that some percentage of the grants they review will be funded, and they have no conceivable incentive to select the poor proposals over good ones.

Roy’s suggestion that scientists review proposals outside their funding pool would not eliminate conflict of interest (Where none exists), but it would eliminate the expert, informed judgments that are the principal ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies